Qiagen Dirección
Dirección controles de criterios 4/4
El CEO de Qiagen's es Thierry Bernard , nombrado en Oct 2019, tiene una permanencia de 4.5 años. compensación anual total es $1.99M, compuesta por 49.1% salario y 50.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $9.73M. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 9.8 años, respectivamente.
Información clave
Thierry Bernard
Chief Executive Officer (CEO)
US$2.0m
Compensación total
| Porcentaje del salario del CEO | 49.1% |
| Permanencia del CEO | 4.6yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 6.3yrs |
| Promedio de permanencia en la Junta Directiva | 9.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
Feb 13Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings
Jan 23These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well
Dec 08An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued
Oct 24Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
Sep 09Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Sep 04Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jul 17Qiagen: Major Asset Growth Needed In Post-Covid World
Jun 22Is Qiagen (NYSE:QGEN) Using Too Much Debt?
May 23Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Apr 18Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly
Feb 15Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued
Feb 14Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated
Feb 07If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity
Jan 18Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases
Jan 06A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Jan 04Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati
Dec 13Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M
Nov 07We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt
Oct 31Qiagen stock down after BHF downgrades rating to Neutral
Oct 10Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)
Oct 04Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate
Sep 14Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
Aug 25Is Qiagen (NYSE:QGEN) Using Too Much Debt?
Jul 28Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio
Jul 15Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?
Jun 29Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?
May 26Is Qiagen (NYSE:QGEN) A Risky Investment?
Apr 29Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?
Mar 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$337m |
| Dec 31 2023 | US$2m | US$979k | US$341m |
| Sep 30 2023 | n/a | n/a | US$485m |
| Jun 30 2023 | n/a | n/a | US$490m |
| Mar 31 2023 | n/a | n/a | US$505m |
| Dec 31 2022 | US$10m | US$950k | US$423m |
| Sep 30 2022 | n/a | n/a | US$488m |
| Jun 30 2022 | n/a | n/a | US$539m |
| Mar 31 2022 | n/a | n/a | US$563m |
| Dec 31 2021 | US$2m | US$900k | US$513m |
| Sep 30 2021 | n/a | n/a | US$311m |
| Jun 30 2021 | n/a | n/a | US$480m |
| Mar 31 2021 | n/a | n/a | US$449m |
| Dec 31 2020 | US$2m | US$900k | US$359m |
| Sep 30 2020 | n/a | n/a | US$191m |
| Jun 30 2020 | n/a | n/a | US$14m |
| Mar 31 2020 | n/a | n/a | -US$31m |
| Dec 31 2019 | US$1m | US$650k | -US$41m |
Compensación vs. Mercado: La compensación total de Thierry($USD1.99M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD8.28M).
Compensación vs. Ingresos: La compensación de Thierry ha sido consistente con los resultados de la empresa en el último año.
CEO
Thierry Bernard (58 yo)
4.6yrs
Permanencia
US$1,991,874
Compensación
Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board since 2021 and had been its Interim Chief Executive Officer since Octo...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Member of Management Board | 4.6yrs | US$1.99m | 0.11% $ 9.9m | |
| CFO, MD & Member of Management Board | 20.3yrs | US$1.07m | 0.16% $ 14.9m | |
| Senior VP & Head of Global Operations | 2.1yrs | sin datos | sin datos | |
| Vice President of Corporate Communications & Investor Relations | 13.6yrs | sin datos | sin datos | |
| Senior VP & Head of Human Resources | 4.6yrs | sin datos | sin datos | |
| Senior Vice President of Life Science Business Area | 6.3yrs | sin datos | sin datos | |
| Senior Director & Head of External Communications | no data | sin datos | sin datos | |
| Senior VP & Head of Molecular Diagnostics Business Area | 9yrs | sin datos | sin datos | |
| Senior Vice President of Qiagen Digital Insights Business Area | 6.3yrs | sin datos | sin datos |
6.3yrs
Permanencia media
52.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de QGEN es experimentado (6.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board | 20.3yrs | US$86.50k | 0.19% $ 17.6m | |
| Independent Member of the Supervisory Board | 12.9yrs | US$101.50k | 0.022% $ 2.1m | |
| Independent Member of the Supervisory Board | 1.9yrs | US$68.50k | sin datos | |
| Independent Chairman of Supervisory Board | 10.9yrs | US$188.50k | 0.0067% $ 632.9k | |
| Independent Member of the Supervisory Board | 3.3yrs | US$82.50k | 0.0012% $ 111.8k | |
| Independent Member of the Supervisory Board | 9.9yrs | US$79.50k | 0.0019% $ 173.7k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board | 8.3yrs | US$68.50k | 0.0076% $ 709.9k | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos |
9.9yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de QGEN se considera experimentada (9.8 años de antigüedad promedio).